Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19046409 | 0.80 | TSHR (0.50) | CYP3A4TSHRCYP2D6MEN1TP53 | |
| SCHEMBL31011762 | 0.79 | OPRM1 (0.34) | CYP3A4CYP2D6USP2CYP1A2CYP2C19 | |
| SCHEMBL22182595 | 0.79 | HIF1A (0.36) | CYP3A4TSHRCYP2D6USP2CYP1A2 | |
| SCHEMBL22025563 | 0.79 | USP2 (0.33) | CYP3A4TSHRCYP2D6USP2CYP1A2 | |
| SCHEMBL15696995 | 0.76 | CYP3A4 (0.30) | CYP3A4TSHRCYP2D6 | |
| SCHEMBL23278020 | 0.76 | USP2 (0.35) | CYP3A4TSHRCYP2D6USP2CYP1A2 | |
| SCHEMBL17611220 | 0.74 | TSHR (0.32) | CYP3A4TSHRCYP2D6CYP2C19 | |
| SCHEMBL19504448 | 0.74 | — | — | |
| SCHEMBL31757571 | 0.74 | TSHR (0.32) | CYP3A4TSHRCYP2D6MEN1TP53 | |
| SCHEMBL27306428 | 0.74 | CYP3A4 (0.35) | CYP3A4TSHRCYP2D6MEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | NOVARTIS PHARMA AG (CH) | 2025-12-23 | — | — | US | claimed |
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, ADRM1, PRMT1 | CYP3A4 2855/4885TSHR 2685/4885CYP2D6 3645/4885 |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | CYP3A4 4780/4885TSHR 4487/4885CYP2D6 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.